Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IBI 322

Next Previous
Drug Profile

IBI 322

Alternative Names: Anti-CD47/PD-L1 bispecific antibody; IBI-322; Recombinant anti-human CD47/PD-L1 bispecific antibody - Innovent Biologics

Latest Information Update: 17 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innovent Biologics
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD4-positive T-lymphocyte stimulants; CD47 antigen inhibitors; Phagocyte stimulants; Programmed cell death-1 ligand-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Haematological malignancies; Solid tumours

Most Recent Events

  • 17 Oct 2023 IBI 322 is still in phase I trial for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT04328831)
  • 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral, Injection)
  • 28 Aug 2023 Innovent Biologics completes a phase I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Parenteral) (NCT04328831)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top